Research & Development

Research & Development

Science First. Claims Only When Earned. Independent laboratory validation is our next major milestone.

The Problem We Are Solving

A Global Crisis Hidden in Plain Sight

7.7M
deaths per year from bacterial infections
21,000+
lives lost every single day
1 in 8
global deaths linked to bacterial infections

These are not statistics about rare diseases or distant outbreaks. They are the result of everyday bacterial exposure — including in wounds and the products used to treat them. LifeShield is developing antimicrobial gauze pads and rolled gauze designed with the goal of addressing bacterial contamination at the point of wound care.

Source: The Lancet

Our Approach

Science First. Claims Only When Earned.

LifeShield Technologies is an early-stage biotechnology company. We are in active development of our proprietary antimicrobial technology for gauze pads and rolled gauze. We have not yet completed independent laboratory validation — and that is our next major milestone. We will not make efficacy claims until that validation is complete and the results are credible and reproducible.

This is not a limitation — it is a commitment. We believe the most important thing a science-driven company can do is be honest about where it is in its development. Premature claims erode trust. We are building ours carefully, one validated milestone at a time.

Development Roadmap

Where We Are and Where We Are Going

2024 — Stage 1In Progress

Foundation & Formulation

Company formation, initial R&D, and development of our proprietary antimicrobial formulation for gauze pads and rolled gauze. Intellectual-property protections being pursued.

2025 — Stage 2Upcoming

Prototype Development & Seed Funding

Prototype manufacturing of Advanced Gauze Pads and Advanced Rolled Gauze. Seed funding to accelerate formulation development and prepare for independent testing.

2025–2026 — Stage 3Planned

Independent Laboratory Validation

Third-party testing by accredited laboratories using standardized protocols — the most important milestone in our roadmap. No performance claims will be made until this stage is complete.

2026 — Stage 4Planned

Manufacturing Partnerships & Scale

Establishing manufacturing partnerships to integrate validated gauze technology into production at scale. Evaluating expansion into apparel and bedding applications.

2026+ — Stage 5Future

Market Launch & Growth

Commercial launch of validated gauze products. Ongoing research, regulatory engagement, and expansion into additional textile product categories.

Our Commitment

What We Promise

No Unverified Claims

We will not publish efficacy data, performance statistics, or validation results until they have been independently verified by accredited third-party laboratories. This applies to gauze and every future product.

Transparent Progress

We will communicate openly about where we are in our development — including what has not yet been proven, setbacks, pivots, and milestones — with our investors, partners, and the public.

Rigorous Standards

When we do test, we will use the highest applicable standards — the kind that would satisfy regulators, peer reviewers, and the scientific community. Independent validation is non-negotiable.

Want to Follow Our Progress?

We share updates with our investor and partner network as we reach key development milestones. Independent laboratory validation is our next major update.

LifeShield

Developing proprietary antimicrobial technology for gauze pads, rolled gauze, apparel, bed sheets, and pillowcases — protecting people from harmful bacteria through the products they already rely on.

© 2026 LifeShield Technologies. All rights reserved.

All technology, formulations, and processes described herein are proprietary and confidential. Unauthorized reproduction or disclosure is strictly prohibited.